Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
Oral Oncol
; 128: 105847, 2022 05.
Article
en En
| MEDLINE
| ID: mdl-35367788
ABSTRACT
INTRODUCTION:
Cemiplimab, a monoclonal antibody directed against the PD-1 receptor of immune cells, has recent indication for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). CASE DESCRIPTION We present the clinical case of an elderly woman affected by locally advanced squamous carcinoma of the left cheek, in excellent response after only one course of therapy with cemiplimab, with good tolerability.CONCLUSIONS:
Immunotherapy is a new therapeutic option in cSCC.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Carcinoma de Células Escamosas
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Oral Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2022
Tipo del documento:
Article